Clark Estates Inc’s Alexion Pharmaceuticals ALXN Stock Holding History

Clark Estates Inc’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-29,000	Closed	-$5.33M	–	101
2021 Q2	$5.33M	Hold	29,000	–	–	0.7%	36
2021 Q1	$4.43M	Hold	29,000	–	–	0.57%	49
2020 Q4	$4.53M	Hold	29,000	–	–	0.64%	40
2020 Q3	$3.32M	Buy	+29,000	New	+$3.13M	0.54%	48

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Clark Estates Inc's ALXN Position: Q3 2021 in Review

Clark Estates Inc sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 29,000 shares — an estimated $5.33M sold.

Clark Estates Inc first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $5.33M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Clark Estates Inc reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Clark Estates Inc sold 29,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $5.33M.
Clark Estates Inc first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Clark Estates Inc's Alexion Pharmaceuticals position peaked at $5.33M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Clark Estates Inc's 13F filing for Q3 2021, filed 12 Nov 2021.